Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 9Phase 1/2 4Phase EARLY_PHASE1 2Phase 3 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × MART-1 Antigen × Dermatologic × Clear all
NCT00074230 2015-05-12

Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

University Hospital Erlangen

Phase 1/2 Completed
82 enrolled
Dermatologic

Melanoma

NCT00010309 2014-01-06

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Dermatologic

Melanoma

NCT00002952 2013-09-05

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

University of Chicago

Phase 1/2 Completed
20 enrolled
Dermatologic

Melanoma

NCT00019214 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1/2 Completed
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡